Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation-Reference-Cited by-同舟云学术

Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation

Published:2017-09 Issue:12 Volume:70 Page:1455-1462
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Pastori Daniele,Nocella Cristina,Farcomeni Alessio,Bartimoccia Simona,Santulli Maria,Vasaturo Fortunata,Carnevale Roberto,Menichelli Danilo,Violi Francesco,Pignatelli Pasquale,Saliola Mirella,Casciaro Marco Antonio,Ferro Domenico,Vicario Tommasa,Albanese Fabiana,Cribari Francesco,Paladino Alberto,Del Sole Francesco,Novo Marta,Cammisotto Vittoria,Andreozzi Paola,Di Stefano Tiziana,Iannucci Patrizia,Sabbatini Elio

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference27 articles.

1. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study;Wolf;Stroke,1991

2. Atrial fibrillation and myocardial infarction: a systematic review and appraisal of pathophysiologic mechanisms;Violi;J Am Heart Assoc,2016

3. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease;Minuz;Circulation,2002

4. Effects of blood pressure on the prothrombotic risk in 1235 patients with non-valvular atrial fibrillation;Varughese;Heart,2007

5. Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation;Pastori;Am Heart J,2015

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of PCSK9 on thrombosis and haemostasis in a variety of metabolic states: Lipids and beyond (Review);International Journal of Molecular Medicine;2024-05-10

2. Efficacy and safety of PCSK9 inhibitors for stroke prevention: Systematic review and meta-analysis;Journal of Stroke and Cerebrovascular Diseases;2024-04

3. Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?;Pharmacological Research;2024-02

4. PCSK-9 inhibitors: a new direction for the future treatment of ischemic stroke;Frontiers in Pharmacology;2024-01-11

5. Renin‐angiotensin-aldosterone system inhibitors and mortality risk in elderly patients with atrial fibrillation. Insights from the nationwide START registry;European Journal of Internal Medicine;2024-01